Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin

Journal of Infectious Diseases

Volumn 201, Issue 11, 2010, Pages 1663-1671

  Kurbanov, Fuat ^a   Tanaka, Yasuhito ^a   Matsuura, Kentaro ^a   Sugauchi, Fuminaka ^a   Elkady, Abeer ^a   Khan, Anis ^a   Hasegawa, Izumi ^b   Ohno, Tomoyoshi ^b   Tokuda, Hiroshi ^c   Mizokami, Masashi ^a,d  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b CHUKYO HOSPITAL   (Japan)

^c Nagoya Municipal Johoku Hospital   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ARGININE; CORE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUTAMINE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAPANESE; LIVER CELL; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MOLECULAR CLONING; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; JAPAN; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; VIRAL CORE PROTEINS;

EID: 77951904098     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/652500     Document Type: Article

References (17)

1. Ray Kim W. Global epidemiology and burden of hepatitis C. Microbes Infect 2002; 4: 1219-1225.
2. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-S244.
3. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus lb infection. N Engl J Med 1996; 334: 77-81.
4. Pascu M, Martus P, Hohne M, et al. Sustained virological response in hepatitis C virus type lb infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 2004; 53: 1345-1351.
5. Shirakawa H, Matsumoto A, Joshita S, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48: 1753-1760.
6. Akuta N, Suzuki F, Kawamura Y, et al. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 2007; 50: 361-368.
7. Mori N, Imamura M, Kawakami Y, et al. Randomized trial of highdose interferon-α-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/ NS5A region and virological response to interferon therapy. J Med Virol 2009; 81: 640-649.
8. Kuiken C, Combet C, Bukh J, et al. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology 2006; 44: 1355-1361.
9. Tateno C, Yoshizane Y, Saito N, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165: 901-912.
10. Kurbanov F, Tanaka Y, Chub E, et al. Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1-2k/1b. J Infect Dis 2008; 198: 1448-1456.
11. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment- finding the right path. Nat Rev Drug Discov 2007; 6: 991-1000.
12. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-410.
13. Akuta N, Suzuki F, Sezaki H, et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype lb and high viral load. J Med Virol 2006; 78: 83-90.
14. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
15. Cuevas JM, Torres-Puente M, Jimenez-Hernandez N, et al. Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin. PLoS One 2008; 3:e3058.
16. Akuta N, Suzuki F, Hirakawa M, et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009; 81: 452-428
17. Yoshioka K, Ito H, Watanabe K, et al. Interferon sensitivity-determining region of nonstructural region 5A of hepatitis C virus genotype lb correlates with serum alanine aminotransferase levels in chronic infection. J Viral Hepat 2005; 12: 139-145.